Daewoong Pharmaceutical’s Pexuclu Achieves a 90% Ulcer Healing Rate After Gastric Endoscopic Procedures
- Input
- 2026-11-20 09:29:21
- Updated
- 2026-11-20 09:29:21

Daewoong Pharmaceutical Co., Ltd. said on the 20th that a clinical trial evaluating Pexuclu’s effectiveness in healing artificial gastric ulcers after endoscopic submucosal dissection (ESD) found a higher complete healing rate than with esomeprazole, an existing gastric acid secretion inhibitor.
ESD is a procedure that removes tumors from the gastric lining using an endoscope. Because part of the gastric lining is removed during the procedure, an artificial gastric ulcer forms at the site. Treatment that suppresses gastric acid secretion to help the ulcer heal is needed, as failure of the wound to heal properly can lead to complications such as bleeding.
The trial was conducted at multiple medical institutions from June 2024 to October 2025 using a double-blind design in which neither patients nor researchers knew which drug was administered. A total of 107 patients received either Pexuclu 40 mg or esomeprazole 40 mg once daily for eight weeks, and the researchers compared ulcer size and whether the ulcers had healed completely, among other measures.
At eight weeks, 90.2% of patients in the Pexuclu group had achieved complete ulcer healing. This was 15.2 percentage points higher than the 75.0% in the esomeprazole group. The difference was also statistically significant (p=0.040). In other words, about nine out of every 10 patients treated with Pexuclu had completely healed ulcers within eight weeks.
The time needed for ulcers to heal was also shorter. The estimated time to complete healing was 40.31 days in the Pexuclu group, about seven days less than the 47.22 days in the esomeprazole group. The percentage reduction in ulcer size at weeks four and eight was also greater in the Pexuclu group. Positive results related to healing time were observed even among patients with large ulcers measuring 800 mm2 or more.
The findings were presented at domestic and international academic conferences, including SIDDS 2026 and UEG 2026. The paper was accepted for publication in the international journal World Journal of Gastroenterology on September 28 and is scheduled for publication in January 2027.
Professor Heo Cheol-ung of Yongin Severance Hospital, the lead investigator, said, “Pexuclu healed gastric ulcers after ESD at a higher rate and more quickly than existing treatments, while showing a similar level of safety. It is significant that it shortened the time to complete healing by about seven days.”
[email protected] Jung Sang-hee Reporter